GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

plonmarlimab   Click here for help

GtoPdb Ligand ID: 11644

Synonyms: TJ 003234 | TJ003234 | TJM2
Immunopharmacology Ligand
Compound class: Antibody
Comment: Plonmarlimab (TJM2/TJ003234) is a humanized IgG1 monoclonal antibody that is designed to neutralise granulocyte-macrophage colony-stimulating factor (GM-CSF; CSF2) cytokine activity. It was developed by I-Mab Biopharma for potential to treat autoimmune diseases, and is likely to be Hu23F4-27 as claimed in I-Mab patent WO2018050111A1 [2].

COVID-19: Plonmarlimab is being evaluated as a mechanism to down-regulate elevated inflammation/cytokine release syndrome in patients with COVID-19 [1] in a Phase 2/3 study.
No information available.
Summary of Clinical Use Click here for help
Plonmarlimab (TJM2/TJ003234) has advanced to clinical evaluations to determine safety and anti-inflammatory efficacy, principally for autoimmune diseases.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT03794180 Study of TJ003234 (Anti-GM-CSF Monoclonal Antibody) in Healthy Adult Subjects Phase 1 Interventional I-Mab Biopharma Co. Ltd.
NCT04341116 Study of TJ003234 (Anti-GM-CSF Monoclonal Antibody) in Subjects With Severe Coronavirus Disease 2019 (COVID-19) Phase 2/Phase 3 Interventional I-Mab Biopharma Co. Ltd.
NCT04457856 A Study of TJ003234 in Rheumatoid Arthritis Patients Phase 1 Interventional I-Mab Biopharma Co. Ltd. Patient dosing in this study began in August 2020.